AMBODRYL Drug Patent Profile
✉ Email this page to a colleague
When do Ambodryl patents expire, and when can generic versions of Ambodryl launch?
Ambodryl is a drug marketed by Parke Davis and is included in one NDA.
The generic ingredient in AMBODRYL is bromodiphenhydramine hydrochloride. There are two drug master file entries for this compound. Additional details are available on the bromodiphenhydramine hydrochloride profile page.
Summary for AMBODRYL
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 40 |
Patent Applications: | 89 |
DailyMed Link: | AMBODRYL at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for AMBODRYL
US Patents and Regulatory Information for AMBODRYL
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Parke Davis | AMBODRYL | bromodiphenhydramine hydrochloride | CAPSULE;ORAL | 007984-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |